SNDX
Syndax Pharmaceuticals, Inc.20.72
-0.16-0.77%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.80BP/E (TTM)
-Basic EPS (TTM)
-3.60Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Syndax Pharmaceuticals ramped up revenue to $45.9 million in Q3 FY2025 ended September 30, 2025, a sharp y/y jump from $12.5 million, driven by $32.0 million in Revuforj product sales (up 12% q/q) and $13.9 million from Niktimvo collaboration profits. While operating expenses held steady at $103.3 million y/y, net loss narrowed to $60.7 million from $84.1 million, with the gap to operating loss mainly from $8.3 million royalty interest expense on the November 2024 Royalty Pharma deal for $350 million upfront (capped at $822.5 million). Cash and equivalents dipped to $116.8 million, offset by $339.3 million in short- and long-term investments; free cash flow not disclosed in the 10-Q. Revuforj prescriptions surged 25% q/q to 850. Yet competition from approved cGVHD therapies like Jakafi looms large.
8-K
Syndax Q3 revenue surges
Syndax Pharmaceuticals reported Q3 2025 financials with $45.9 million total revenue, up from prior periods, driven by $32.0 million in Revuforj net revenue (12% quarter-over-quarter growth) and $13.9 million from Niktimvo collaboration, reflecting strong demand in relapsed/refractory AML and chronic GVHD markets. Revuforj gained FDA approval on October 24, 2025, for R/R NPM1-mutated AML, expanding its label as the first therapy for both NPM1 and KMT2A indications, while multiple frontline trials advance. Cash reserves stand at $456.1 million, funding operations to profitability amid stable expenses. Yet, net loss narrowed to $60.7 million.
8-K
FDA approves Revuforj for NPM1 AML
Syndax Pharmaceuticals scored FDA approval for Revuforj on October 24, 2025, targeting relapsed or refractory NPM1-mutated AML in adults and kids over one year old with no other options. This second nod, after last year's KMT2A translocation win, stems from AUGMENT-101 trial data showing 23% complete remission rates and a 4.5-month median duration. Revuforj launches commercially soon. Differentiation syndrome risks loom large.
10-Q
Q2 FY2025 results
Syndax Pharmaceuticals ramped up revenue to $38.0M in Q2 2025 ended June 30, up sharply from $3.5M y/y and $19.6M q/q (derived), fueled by $28.6M in Revuforj product sales—43% higher than Q1—and $9.4M from Niktimvo collaboration, while gross margin on products held at ~95.5%. Operating loss narrowed to $69.4M from $74.2M y/y, yet widened q/q to $153.1M YTD amid surging R&D ($62.2M, +28% y/y) on revumenib trials and a $5.0M milestone, plus SG&A ($43.8M, +51% y/y) for commercialization; net loss hit $71.8M, or $(0.83) diluted EPS on 86.3M shares, matching basic with no anti-dilution. Cash and equivalents dipped to $108.6M from $154.1M year-end, with $517.9M total liquidity supporting ops despite $183.0M YTD burn; free cash flow not disclosed in the 10-Q. Royalty financing liability stood at $343.8M (9.08% effective rate). Competition in oncology pipelines poses ongoing pressure.
8-K
Strong Q2 revenue growth
Syndax Pharmaceuticals reported robust Q2 2025 results, with Revuforj net revenue surging 43% to $28.6 million despite a third of KMT2A patients pausing for transplants, while Niktimvo generated $36.2 million in net revenue—its first full quarter—yielding $9.4 million in collaboration revenue for Syndax. The FDA granted Priority Review to Revuforj's sNDA for R/R mNPM1 AML, targeting approval by October 25, 2025, amid ongoing frontline trials. Cash reserves hit $517.9 million, funding operations to profitability. Revuforj's momentum builds steadily.
ABVX
Abivax SA
110.98-6.93
ATXS
Astria Therapeutics, Inc.
12.87-0.05
BLRX
BioLineRx Ltd.
3.01-0.17
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
INCY
Incyte Corporation
97.03-1.61
NUVB
Nuvation Bio Inc.
8.66+0.15
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
RNXT
RenovoRx, Inc.
0.84-0.10
TENX
Tenax Therapeutics, Inc.
11.16+0.55
TOVX
Theriva Biologics, Inc.
0.21+0.01